Kuros Biosciences (XSWX:KURN) Total Inventories : CHF4.86 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Total Inventories?

Kuros Biosciences's total inventories for the quarter that ended in Dec. 2023 was CHF4.86 Mil. Kuros Biosciences's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was CHF4.62 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Kuros Biosciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was CHF0.17.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Kuros Biosciences's Days Inventory for the six months ended in Dec. 2023 was 112.69.

Inventory Turnover measures how fast the company turns over its inventory within a year. Kuros Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.62.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Kuros Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.22.

Kuros Biosciences Total Inventories Historical Data

The historical data trend for Kuros Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Total Inventories Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.95

1.46

1.76

3.17

4.86

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial															1.76	2.34	3.17	4.39	4.86

Kuros Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Kuros Biosciences (XSWX:KURN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Kuros Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(13.866	+	0.75 * 6.411	+	0.5 * 4.856	-	14.752
-	0	-	0)	/	36.7669
=	0.17

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kuros Biosciences's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	4.6225	/	7.486	*	365 / 2
	=	112.69

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kuros Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	7.486	/	4.6225
	=	1.62

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kuros Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	4.6225	/	20.698
	=	0.22

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Kuros Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines